Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK 325.90
+1.40 (0.43%)
Aug 15, 2025, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B
Revenue Growth
+20.90%
P/S Ratio
4.64
Revenue / Employee
3.98M
Employees
77,349
Market Cap
1,448.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.79B |
| Genmab | 23.16B |
| Demant | 22.59B |
| ALK-Abelló | 5.71B |
| H. Lundbeck | 23.52B |
| Zealand Pharma | 9.11B |
| Ambu A/S | 5.83B |
| Bavarian Nordic | 6.23B |
Novo Nordisk News
- 16 hours ago - INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO - PRNewsWire
- 17 hours ago - Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead - Seeking Alpha
- 19 hours ago - Novo Nordisk wins FDA label expansion for Wegovy against liver disease MASH - Seeking Alpha
- 19 hours ago - 11 Dividend Aristocrats With Excellent Upside Potential In The Next Year - Seeking Alpha
- 1 day ago - Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH - Reuters
- 1 day ago - Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH - GlobeNewsWire
- 1 day ago - Why Novo Nordisk Flew Almost 3% Higher on Friday - The Motley Fool
- 1 day ago - NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit - PRNewsWire